{"protocolSection": {"identificationModule": {"nctId": "NCT02062645", "orgStudyIdInfo": {"id": "CVAA489ATR04"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of Efficacy and Safety of CVAA489 in Hypertensive Patients", "officialTitle": "A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge\u00ae (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-02"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-12", "studyFirstSubmitQcDate": "2014-02-12", "studyFirstPostDateStruct": {"date": "2014-02-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-11-15", "resultsFirstSubmitQcDate": "2017-02-07", "resultsFirstPostDateStruct": {"date": "2017-03-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-02-07", "lastUpdatePostDateStruct": {"date": "2017-03-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["essential hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 115, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "amlodipine/valsartan", "type": "EXPERIMENTAL", "description": "All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.", "interventionNames": ["Drug: amlodipine/valsartan"]}], "interventions": [{"type": "DRUG", "name": "amlodipine/valsartan", "description": "Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg", "armGroupLabels": ["amlodipine/valsartan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8", "description": "Control rate of BP defined as BP lower than 140/90 mmHg at office visits", "timeFrame": "At week 4 and 8"}], "secondaryOutcomes": [{"measure": "Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8", "description": "Change in systolic blood pressure measured in office from baseline at week 4 and 8.", "timeFrame": "baseline, week 4, week 8"}, {"measure": "Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8", "description": "Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.", "timeFrame": "baseline, week 4, week 8"}, {"measure": "Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8", "description": "Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\\>100 mEq/day)", "timeFrame": "At week 4 and 8"}, {"measure": "SBP and DBP in Patients With High Sodium Intake at Week 4 and 8", "description": "Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.", "timeFrame": "At week 4 and 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, above 18 years of age\n* Diagnosis of essential hypertension\n* Newly diagnosed,\n* Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1-month period)\n* Written informed consent\n\nExclusion Criteria:\n\n* Known or suspected secondary hypertension\n* eGFR lower than 30 mL/min\n* Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase\n* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)\n* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.\n* Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women\n* Other protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Novartis Investigative Site", "city": "Canakkale", "country": "Turkey", "geoPoint": {"lat": 40.15552, "lon": 26.41271}}, {"facility": "Novartis Investigative Site", "city": "Fatih / Istanbul", "zip": "34098", "country": "Turkey"}, {"facility": "Novartis Investigative Site", "city": "Kinikli / Denizli", "zip": "20070", "country": "Turkey"}, {"facility": "Novartis Investigative Site", "city": "Kocaeli", "zip": "41380", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}, {"facility": "Novartis Investigative Site", "city": "Malatya", "zip": "44280", "country": "Turkey", "geoPoint": {"lat": 38.35018, "lon": 38.31667}}, {"facility": "Novartis Investigative Site", "city": "Mersin", "zip": "33079", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Novartis Investigative Site", "city": "Talas / Kayseri", "zip": "38039", "country": "Turkey"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "One hundred thirty patients were screened and 115 were enrolled into the trial.", "groups": [{"id": "FG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "100"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The baseline population was the ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0)", "groups": [{"id": "BG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "100"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.06", "spread": "11.22"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "45"}]}]}]}, {"title": "Systolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHG", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.3", "spread": "13.2"}]}]}]}, {"title": "Diastolic blood pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "96.7", "spread": "12.7"}]}]}]}, {"title": "Heart rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "beats/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "80.15", "spread": "10.00"}]}]}]}, {"title": "Body mass index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.19", "spread": "5.32"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8", "description": "Control rate of BP defined as BP lower than 140/90 mmHg at office visits", "populationDescription": "The ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0). One hundred patients had BP measurements at Visit 2 and 91 patients at Visit 3. LOCF (Visit 2 to Visit 3). Analysis performed both with original and imputed values", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "At week 4 and 8", "groups": [{"id": "OG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}]}], "classes": [{"title": "Week 4 Systolic (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.0"}]}]}, {"title": "Week 4 Diastolic (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.0"}]}]}, {"title": "Week 4 Overall Blood Pressure(n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.0"}]}]}, {"title": "Week 8 Systolic(n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "70.3"}]}]}, {"title": "Week 8 Diastolic (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.4"}]}]}, {"title": "Week 8 Overall Blood Pressure (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.0"}]}]}, {"title": "Week 8 Systolic (LOCF) (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.0"}]}]}, {"title": "Week 8 Diastolic (LOCF) (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.0"}]}]}, {"title": "Week 8 Overall Blood Pressure (LOCF) (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.0"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8", "description": "Change in systolic blood pressure measured in office from baseline at week 4 and 8.", "populationDescription": "The ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0). One hundred patients had BP measurements at Visit 2 and 91 patients at Visit 3. LOCF (Visit 2 to Visit 3). Analysis performed both with original and imputed values", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline, week 4, week 8", "groups": [{"id": "OG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}]}], "classes": [{"title": "Systolic blood pressure (SBP) Day 0 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.3", "spread": "13.2"}]}]}, {"title": "Systolic blood pressure (SBP) Week 4 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.17", "spread": "14.05"}]}]}, {"title": "Systolic blood pressure (SBP) Week 8 (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "134.04", "spread": "13.51"}]}]}, {"title": "Systolic blood pressure (SBP) Week 8 LOCF (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "134.71", "spread": "13.37"}]}]}, {"title": "Decrease in Systolic Week 4 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.15", "spread": "18.18"}]}]}, {"title": "Decrease in Systolic Week 8 (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.22", "spread": "18.25"}]}]}, {"title": "Decrease in Systolic BP Week 8 LOCF (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.61", "spread": "17.81"}]}]}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8", "description": "Change in diastolic blood pressure measured in office from baseline at week 4 and week 8.", "populationDescription": "The ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0). One hundred patients had BP measurements at Visit 2 and 91 patients at Visit 3. LOCF (Visit 2 to Visit 3). Analysis performed both with original and imputed values", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline, week 4, week 8", "groups": [{"id": "OG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}]}], "classes": [{"title": "Diastolic blood pressure (DBP) Day 0 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.66", "spread": "12.68"}]}]}, {"title": "Diastolic blood pressure (DBP) Week 4 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.0", "spread": "9.88"}]}]}, {"title": "Diastolic blood pressure (DBP) Week 8 (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.04", "spread": "8.66"}]}]}, {"title": "Diastolic blood pressure (DBP) Week 8 LOCF (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.37", "spread": "8.69"}]}]}, {"title": "Decrease in Diastolic BP Week 4 (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.66", "spread": "12.58"}]}]}, {"title": "Decrease in Diastolic BP Week 8 (n=91)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.54", "spread": "13.19"}]}]}, {"title": "Decrease in Diastolic BP Week 8 LOCF (n=100)", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.29", "spread": "12.73"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8", "description": "Control rate of BP is defined as blood pressure lower than 140/90 mmHg at office visits in patients with high sodium intake (\\>100 mEq/day)", "populationDescription": "The ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0). One hundred patients had BP measurements at Visit 2 and 91 patients at Visit 3. LOCF (Visit 2 to Visit 3). Analysis performed both with original and imputed values", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "At week 4 and 8", "groups": [{"id": "OG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}]}], "classes": [{"title": "Week 4 (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.6"}]}]}, {"title": "Week 8 (n=64)", "categories": [{"measurements": [{"groupId": "OG000", "value": "64.1"}]}]}, {"title": "Week 8 LOCF (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.9"}]}]}]}, {"type": "SECONDARY", "title": "SBP and DBP in Patients With High Sodium Intake at Week 4 and 8", "description": "Change in systolic and diastolic blood pressure measured in office from baseline at week 4 and 8.", "populationDescription": "All patients received amlodipine/valsartan 160/5 mg daily at Day 0 and were up titrated to amlodipine/valsartan 160/10 mg daily at visit 2 (week 4) if their hypertension can not be controlled. The duration of treatment period was 8 weeks.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "At week 4 and 8", "groups": [{"id": "OG000", "title": "Amlodipine/Valsartan", "description": "All patients received amlodipine/valsartan 5/160 mg daily at Day 0 and were up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (week 4) if their hypertension was not controlled. The duration of treatment period was 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}]}], "classes": [{"title": "SBP at Week 4 (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.01", "spread": "13.67"}]}]}, {"title": "SBP at Week 8 (n=64)", "categories": [{"measurements": [{"groupId": "OG000", "value": "134.20", "spread": "13.24"}]}]}, {"title": "SBP at Week 8 LOCF (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "134.84", "spread": "13.17"}]}]}, {"title": "DBP at Week 4 (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.73", "spread": "10.26"}]}]}, {"title": "DBP at Week 8 (n=64)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.23", "spread": "8.80"}]}]}, {"title": "DBP at Week 8 LOCF (n=70)", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.47", "spread": "8.91"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "description": "The safety population included data from patients who attended Visit 2 which was 110 patients.", "eventGroups": [{"id": "EG000", "title": "Amlodipine/Valsartan", "description": "amlodipine/valsartan", "seriousNumAffected": 3, "seriousNumAtRisk": 110, "otherNumAffected": 76, "otherNumAtRisk": 110}], "seriousEvents": [{"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 110}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 110}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 110}]}, {"term": "Aortic valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 110}]}, {"term": "Diastolic dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 110}]}, {"term": "Left atrial dilatation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 110}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 110}]}, {"term": "Left ventricular hypertrophy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 110}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 110}]}, {"term": "Tricuspid valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 110}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Electrocardiogram abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Urine sodium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 110}]}, {"term": "Microalbuminuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Pulmonary hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 110}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial"}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000068838", "term": "Amlodipine, Valsartan Drug Combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M319", "name": "Amlodipine, Valsartan Drug Combination", "asFound": "Systemic Embolism", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}